Design and development of ondansetron hydrochloride pH independent control released matrix tablets

The oral control drug delivery is the most acceptable delivery system for patient acceptance, industrial application and economical but still it has several challenges to design a dosage form. The gastro intestinal pHis one of the major limitations for constant drug release due to different pH variations different regions (stomach vs small intestine) throughout the GIT. The aim of the present research work was to develop a pH independent oral control release drug delivery of pH dependent Ondansetron HCl for the treatment of CINV or PONV. The major limitation of the drug was found burst release in SGF pH 1.2 and highly precipitation in intestinal pH (pH 6.8 phosphate buffer). The formulator is challenging to develop constant controlled drug release in entire gastro intestinal tract. The techniques involve the use of pH modulating agents and acidifying agents to achieve pH independent controlled drug release. It was found that incorporation of anionic polymer (Eudragit L100-55) with control release nonionic HPMC matrix shows pH independent drug release in both SGF pH 1.2 and pH 6.8 phosphate buffer. In conclusion it was understood that the release profile of HPMC sellable matrices of Ondansetron HCl with manipulating the micro environmental pH, at variable pH conditions provided a efficient and predictable results.